Aktuellt
SENASTE
OssDsign has updated its strategy and decided to discontinue the Cranial PSI business and focus solely on orthobiologics. All already planned surgeries with Cranial PSI in 2023 will be delivered to customers to avoid a negative impact on patients. This also results in all sales coming from the US market from 2024 forward. OssDsign expects to save SEK 30-40m in opex annually from the discontinuation of Cranial PSI. Our mid-point equity value of SEK 12 is under review.
LÄS MER
